Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study.
Amelia Nur VidyantiLung ChanCheng-Li LinChih-Hsin MuoChung Y HsuYou-Chia ChenDean WuChaur-Jong HuPublished in: PloS one (2019)
Among first-ever ischemic stroke patients, secondary stroke prevention using clopidogrel was associated with higher rates of MACE than aspirin. Aspirin might have better efficacy in secondary stroke prevention and was associated with lower risk of MACE. The real-world evidence raises the need to re-assess the current therapeutic options in secondary stroke prevention applying aspirin vs. clopidogrel.
Keyphrases
- cardiovascular events
- antiplatelet therapy
- atrial fibrillation
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery disease
- low dose
- cardiovascular disease
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- type diabetes
- emergency department
- blood brain barrier